<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Sun, 08 Nov 2009 18:14:26 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Upstream Biosciences' Potential Tropical Disease Treatments Demonstrate Promising Signs of Efficacy at McGill University</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2685899</guid>
      <description><![CDATA[VANCOUVER, BC -- -- 10/07/08 -- Upstream Biosciences Inc. today announced that its second generation of novel antiparasitic agents demonstrated in vitro efficacy against both Leishmaniasis and Trypanosomiasis. Upstream's novel compounds were tested by Dr. Armando Jardim at the Institute of Parasitology of McGill University in Montreal, Quebec, Canada. Upstream continues to collaborate with McGill to perform further testing on its potential tropical disease treatments. The Institute of Parasitology is recognized internationally for its research on infectious parasitic diseases.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2685899>[More...]</a>]]></description>
      <pubDate>Tue, 07 Oct 2008 12:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">UPBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2685899</link>
    </item>
    <item>
      <title>Upstream Biosciences Appoints Dr. Michael Hayden Killam Professor of Medical Genetics and the Canada Research Chair in Human Genetics to Its Scientific Advisory Board</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2666745</guid>
      <description><![CDATA[VANCOUVER, BC -- -- 10/01/08 -- Upstream Biosciences Inc. today announced the appointment of Dr. Michael Hayden, MD, PhD, FRCPC to its Scientific Advisory Board . Dr. Hayden has co-founded three companies: Xenon Pharmaceuticals, Aspreva Pharmaceuticals Inc., and Neurovir. He is currently serving as chief scientific officer for Xenon and chairman of the medical advisory board for Aspreva. Aspreva focuses on repurposing existing drugs to treat rare diseases and was purchased in a deal worth approximately $915 million US by the Galenica Group. Dr. Hayden is a full professor of Medical Genetics at the University of British Columbia as well as Director of the Center for Molecular Medicine and Therapeutics in Vancouver; the CMMT is a gene research center under UBC's Faculty of Medicine.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2666745>[More...]</a>]]></description>
      <pubDate>Wed, 01 Oct 2008 12:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">UPBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2666745</link>
    </item>
    <item>
      <title>Upstream Biosciences Begins Animal Efficacy Testing for Trypanosomiasis Treatment</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2612598</guid>
      <description><![CDATA[VANCOUVER, BC -- -- 09/15/08 -- Upstream Biosciences Inc. announced today that it has begun animal efficacy testing in collaboration with Makerere University in Kampala, Uganda to evaluate its proprietary drug candidates as potential livestock and human treatments for Trypanosomiasis. Management anticipates that this research will lead to the selection of a drug candidate to treat Trypanosomiasis initially in livestock followed by a human treatment for the disease.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2612598>[More...]</a>]]></description>
      <pubDate>Mon, 15 Sep 2008 11:56:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">UPBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2612598</link>
    </item>
    <item>
      <title>Upstream Begins Animal Efficacy Testing for Leishmaniasis Treatment</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2441174</guid>
      <description><![CDATA[Upstream Biosciences Inc. announced today that it is collaborating with Makerere University in Kampala, Uganda to evaluate the efficacy in animals of more than 20 proprietary drug candidates as potential treatments for Leishmaniasis in humans. Drug resistance has greatly reduced the effectiveness of existing Leishmaniasis treatments.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2441174>[More...]</a>]]></description>
      <pubDate>Mon, 28 Jul 2008 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">UPBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2441174</link>
    </item>
    <item>
      <title>Upstream and McGill University to Collaborate on Testing of Potential Tropical Disease Treatments</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2381550</guid>
      <description><![CDATA[Upstream Biosciences Inc. today announced that it has entered into a collaboration with McGill University's Institute of Parasitology in Montreal, Quebec, Canada to begin in vitro testing of the Company's second generation of drug candidates for the potential treatment of tropical diseases leishmaniasis, trypanaosomiasis and malaria.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2381550>[More...]</a>]]></description>
      <pubDate>Wed, 09 Jul 2008 11:56:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">UPBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2381550</link>
    </item>
    <item>
      <title>Upstream Appoints University of North Carolina Chemoinformatics Expert to Scientific Advisory Board</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2312410</guid>
      <description><![CDATA[Upstream Biosciences Inc. today announced the appointment of Alexander Tropsha, Ph.D. of the University of North Carolina , one of the world's leading chemoinformatics experts, to the company's Scientific Advisory Board. Chemoinformatics combines chemistry and computer science to accelerate the speed and reduce the cost of discovering drugs to treat disease.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2312410>[More...]</a>]]></description>
      <pubDate>Wed, 25 Jun 2008 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">UPBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2312410</link>
    </item>
    <item>
      <title>Upstream Biosciences Expects Increased Interest From Big Pharma as FDA's Proposed Priority Review Voucher Program Is Implemented</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2274458</guid>
      <description><![CDATA[Upstream Biosciences Inc. announced today that the United States Food and Drug Administration's proposed priority review voucher program to stimulate development of drugs for tropical diseases could increase and accelerate the financial returns for small companies with the most promising technologies.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2274458>[More...]</a>]]></description>
      <pubDate>Tue, 10 Jun 2008 11:56:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">UPBS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2274458</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=UPBS" rel="self" type="application/rss+xml" />
  </channel>
</rss>